Article
Oncology
Li-Ting Liu, Huai Liu, Ying Huang, Jin-Hao Yang, Si-Yi Xie, Yuan-Yuan Li, Shan-Shan Guo, Bin Qi, Xiao-Yun Li, Dong-Ping Chen, Feng Jin, Xue-Song Sun, Zhen-Chong Yang, Sai-Lan Liu, Dong-Hua Luo, Ji-Bin Li, Qing Liu, Pan Wang, Ling Guo, Hao-Yuan Mo, Fang Qiu, Qi Yang, Yu-Jing Liang, Guo-Dong Jia, Dong-Xiang Wen, Jin-Jie Yan, Chong Zhao, Qiu-Yan Chen, Rui Sun, Lin-Quan Tang, Hai-Qiang Mai
Summary: The efficacy and safety of concurrent adjuvant cisplatin-gemcitabine were compared with cisplatin-fluorouracil in N2-3 nasopharyngeal carcinoma. The 3-year progression-free survival was significantly higher in the cisplatin-gemcitabine group (83.9%) compared to the cisplatin-fluorouracil group (71.5%). The adverse events were similar between the two groups. Therefore, cisplatin-gemcitabine could be considered as an adjuvant therapy option for patients with N2-3 nasopharyngeal carcinoma.
Article
Oncology
Shasha He, Yan Wang, Yulin Lai, Xinping Cao, Yufeng Ren, Yong Chen
Summary: This study evaluated the efficacy and safety of radiotherapy with nedaplatin or cisplatin in patients with locally advanced cervical cancer. The results showed that nedaplatin-based concurrent chemoradiotherapy had significantly higher severe hematologic harms compared to cisplatin-based treatment. However, the 1-year progression-free survival and overall survival rates were similar between the two groups.
FRONTIERS IN ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Hyehyun Jeong, Kyu-pyo Kim, Jae Ho Jeong, Dae Wook Hwang, Jae Hoon Lee, Ki-Hun Kim, Deok-Bog Moon, Myung Ah Lee, Se Jun Park, Hong Jae Chon, Jin-hong Park, Ji Sung Lee, Baek-Yeol Ryoo, Changhoon Yoo
Summary: The effectiveness of adjuvant gemcitabine plus cisplatin (GemCis) therapy was evaluated in a homogeneous group of high-risk patients with resected, lymph node-positive extrahepatic cholangiocarcinoma. The study found that adjuvant GemCis did not improve survival outcomes compared with capecitabine in this patient population.
Article
Health Care Sciences & Services
Dong-Hua Luo, Xiao-Yun Li, Shan -Shan Guo, Wan -Ping Guo, Li -Ting Liu, Hao-Yuan Mo, Ling Guo, Xiao-Fei Lv, Li-Zhi Liu, Ji-Bin Li, Qing Liu, Pan Wang, Xue-Song Sun, Sai-Lan Liu, Qiu-Yan Chen, Lin-Quan Tang, Hai-Qiang Mai
Summary: The study demonstrated the efficacy and safety of the TPF regimen followed by de-escalated radiotherapy with concurrent cisplatin in treating childhood stage IVa-b NPC patients.
LANCET REGIONAL HEALTH-WESTERN PACIFIC
(2023)
Article
Oncology
Ramandeep Singh, Raja Paramjeet Singh Banipal, Lajya Devi Goyal
Summary: Cervical cancer is the fourth leading cause of cancer death in women worldwide and the third most common cancer in India. This study compared the treatment response and toxicities of cisplatin and gemcitabine as concurrent chemoradiotherapy for cervical cancer. The results showed that cisplatin had a better treatment response, but gemcitabine had more hematological toxicity and cisplatin had more gastrointestinal toxicity. The skin toxicities were comparable.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2022)
Article
Oncology
Kazuya Takamochi, Masahiro Tsuboi, Morihito Okada, Seiji Niho, Satoshi Ishikura, Shunsuke Oyamada, Takuhiro Yamaguchi, Kenji Suzuki
Summary: This study investigated the use of concurrent chemoradiotherapy followed by surgery for stage IIIA (N2) lung squamous cell carcinoma (LSCC). The results showed promising outcomes, with high 2-year progression-free survival and overall survival rates. The study suggests that this treatment approach is feasible for LSCC patients.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Yong Li, Zhiying Chen, Xiang Wang, Xiumei Li, Jie Zhou, Yongchun Zhang
Summary: The study found that tumor histology and residual tumor in the cervix were significantly associated with postoperative recurrence, and identified age and residual tumor in the cervix as independent risk factors. Compared to patients with an interval longer than 6 weeks, patients with an interval of less than 6 weeks had statistically significant differences in bleeding and postoperative complications.
Article
Medicine, General & Internal
Feng-Ju Zhao, Qun Su, Wei Zhang, Wen-Cui Yang, Lin Zhao, Li-Ying Gao
Summary: Endo combined with concurrent radiotherapy and chemotherapy for the treatment of advanced cervical squamous cell carcinoma has a positive effect on reducing the level of tumor markers in patients, prolonging the PFS and OS times of patients, and improving the quality of life.
WORLD JOURNAL OF CLINICAL CASES
(2021)
Article
Urology & Nephrology
Sarah M. H. Einerhand, Anna J. Black, Homayoun Zargar, Adrian S. Fairey, Colin P. Dinney, Maria C. Mir, Laura-Maria Krabbe, Michael S. Cookson, Niels-Erik Jacobson, Jeffrey S. Montgomery, Nikhil Vasdev, Evan Y. Yu, Evanguelos Xylinas, Wassim Kassouf, Marc A. Dall'Era, Srikala S. Sridhar, Jonathan S. McGrath, Jonathan Aning, Shahrokh F. Shariat, Jonathan L. Wright, Andrew C. Thorpe, Todd M. Morgan, Jeff M. Holzbeierlein, Trinity J. Bivalacqua, Scott North, Daniel A. Barocas, Yair Lotan, Petros Grivas, Jorge A. Garcia, Andrew J. Stephenson, Jay B. Shah, Siamak Daneshmand, Kamran Zargar-Shoshtari, Philippe E. Spiess, Bas W. G. van Rhijn, Peter C. Black, Laura S. Mertens
Summary: This study compared the clinical outcomes of ≥ 3 cycles of preoperative gemcitabine-carboplatin (gem-carbo) versus gemcitabine-cisplatin (gem-cis) in patients with muscle-invasive bladder cancer (MIBC). The results showed no significant difference between the two chemotherapy regimens in terms of complete pathological response rate and survival outcomes.
WORLD JOURNAL OF UROLOGY
(2022)
Article
Oncology
Poorva Vias, Harpreet Angural, Rajeev Kumar Seam, Manoj Kumar Gupta, Manish Gupta, Vikas Fotedar, Anup Negi
Summary: The study conducted on stages II, III, and IVA of carcinoma cervix for 1 year showed that accelerated radiotherapy (ART) is effective in decreasing the total treatment time for patients with cervical cancer. The results were similar in both groups, but the ART group had more acute toxicities, which were effectively managed.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
(2021)
Review
Oncology
Haonan Liu, Xiao Ma, Chenyu Sun, Meng Wu, Zhiyuan Xu, Shuang Zhou, Nan Yao, Suya Liu, Xiaobing Qin, Zhengxiang Han
Summary: This study assessed the efficacy and safety of adjuvant chemotherapy (ACT) after concurrent chemoradiation (CCRT) in patients with locally advanced cervical cancer (LACC) through a meta-analysis. The results showed that although ACT reduced the risk of local recurrence and distant metastasis, it did not significantly improve the survival rate and the complete response rate. However, it was associated with increased grade 3-4 acute toxicities. Therefore, the use of this ACT regimen is not recommended for patients with LACC.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Supriya Chopra, Nilesh Ranjan, Prachi Mittal
Summary: This article reviews the treatment strategies for early stage cervical cancer and highlights the latest advances in radiation technology and risk stratification research. These developments not only reduce treatment-related adverse events but also provide opportunities to re-evaluate the therapeutic ratio and further develop postoperative risk stratification.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Public, Environmental & Occupational Health
Huafeng Shou, Qiuyan Wan, Hong'en Xu, Lei Shi, Tao Song
Summary: This study evaluated the treatment and prognostic impact of age at diagnosis on stage IIB-IVA cervical cancer patients who received radiotherapy using the SEER database. The results showed that older patients were less likely to receive aggressive treatment and had lower overall survival. Therefore, geriatric assessment should be incorporated into clinical decision-making for elderly cervical cancer patients.
Article
Oncology
Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni
Summary: In this randomized, open-label trial, adjuvant nab-paclitaxel + gemcitabine was compared with gemcitabine alone for resected pancreatic ductal adenocarcinoma. The study found that although nab-paclitaxel + gemcitabine showed favorable overall survival, it did not meet the primary endpoint of independently assessed disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Yan Wang, Chengtao Wang, Shasha He, Li Bai, Fei Kong, Siyang Wang, Lei Cui, Qiang Qin, Yunying Yang, Wei Xiao, Meiyan Zhu, Zeyu Zhang, Yulin Lai, Wenjing Bao, Zhenwei Peng, Yong Chen
Summary: This study aimed to evaluate the noninferiority of docetaxel plus cisplatin (TP) induction chemotherapy regimen compared to docetaxel plus cisplatin plus fluorouracil (TPF) regimen in patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC). The study showed that TP induction chemotherapy regimen was noninferior to TPF regimen in terms of failure-free survival, with fewer side effects.